Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial
Key Takeaways
- Brand Zepbound and compounded tirzepatide share the same active molecule but differ in FDA status, manufacturing standards, and supply chain.
- Lilly Direct's vial program (launched August 2024) prices brand Zepbound vials at $349-$499/month for doses 2.5-10 mg, narrowing the historical cost gap with compounded options.
- For 12.5 mg and 15 mg doses, compounded tirzepatide remains the lower-cost option since Lilly Direct does not offer vials at those strengths.
- Clinical effects should match at equivalent doses; quality depends heavily on the compounding pharmacy when going compounded.
- The compounding pathway narrowed after FDA declared the tirzepatide shortage resolved in October 2024.
Direct answer
Brand Zepbound and compounded tirzepatide contain the same active molecule. Brand Zepbound is FDA-approved, manufactured by Eli Lilly under GMP standards, and available in two formats: prefilled pens (~$1,059/month retail) and Lilly Direct vials ($349-$499/month for doses 2.5-10 mg). Compounded tirzepatide is not FDA-approved, prepared by 503A pharmacies, and typically priced $250-$450/month. The Lilly Direct vial program substantially narrowed what was once a several-hundred-dollar monthly gap. For patients at maximum doses or those needing custom strengths, compounded remains a relevant option.
Get compounded tirzepatide from $349/mo
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Table of contents
- The August 2024 launch that changed the comparison
- The regulatory timeline for tirzepatide
- How Lilly Direct vials work
- How compounded tirzepatide differs in source and format
- The dose-by-dose cost comparison
- Quality control: FDA approval vs 503A pharmacy practice
- Dose flexibility: where compounding still has an edge
- Custom formulations and combination products
- Efficacy comparison: brand trial data and real-world expectations
- The contrary view: when brand Zepbound is the clear answer
- Decision framework
- FAQ
- Sources
The August 2024 launch that changed the comparison
Before August 2024, compounded tirzepatide was substantially cheaper than brand Zepbound. Typical compounded prices: $300-$450/month. Typical brand Zepbound pen prices: $1,059/month retail or $0-$200 with commercial insurance coverage.
Lilly Direct launched in August 2024 with a vial-based cash program:
| Zepbound vial dose | Lilly Direct price (May 2026) |
|---|---|
| 2.5 mg (4-week supply) | $349 |
| 5 mg | $499 |
| 7.5 mg | $499 |
| 10 mg | $499 |
| 12.5 mg | Not available in vial; pen only |
| 15 mg | Not available in vial; pen only |
This pricing put FDA-approved Zepbound within $100-$200/month of typical compounded tirzepatide for doses 2.5-10 mg. Several patients who had been on compounded tirzepatide migrated to Lilly Direct vials once the program became established. The compounded tirzepatide market contracted in 2025 partly because of this price compression, and partly because the shortage-rule compounding pathway closed.
The regulatory timeline for tirzepatide
| Date | Event |
|---|---|
| May 2022 | Mounjaro (tirzepatide for type 2 diabetes) FDA-approved |
| October 2022 | FDA places tirzepatide on drug shortage list |
| 2022-2024 | 503A pharmacies legally compound tirzepatide under shortage rules |
| November 2023 | Zepbound (tirzepatide for chronic weight management) FDA-approved |
| August 2024 | Lilly Direct vial program launches at $399-$549/month initially; lowered in subsequent rounds |
| October 2024 | FDA declares tirzepatide shortage resolved |
| December 2024 | Zepbound approved for obstructive sleep apnea in adults with obesity |
| February 2025 | FDA enforcement against unauthorized tirzepatide compounding intensifies |
| March 2025 | Lilly Direct expanded with 7.5 mg and 10 mg vials |
| May 2025 | SURMOUNT-5 head-to-head results published in NEJM |
The tirzepatide regulatory landscape moved faster than the semaglutide landscape. Lilly launched the vial program months before declaring shortage resolution, ensuring patient access continuity. Novo Nordisk launched NovoCare Direct for Wegovy on a similar timeline.
How Lilly Direct vials work
Lilly Direct is a direct-to-patient sales channel operated through a partnership between Eli Lilly and a third-party pharmacy. Process:
- Patient obtains a Zepbound prescription from a licensed clinician (telehealth or in-person)
- Patient submits the prescription through the Lilly Direct website
- Lilly's pharmacy partner fills the prescription at the Lilly Direct cash price
- Vials ship to the patient directly via cold-chain courier
- Patient self-administers using separately purchased syringes
Key features:
- Cash-pay only; not stackable with insurance copay savings cards
- Vial format requires drawing into a syringe (no prefilled pen at Lilly Direct prices)
- Product is the same Zepbound molecule, manufactured by Lilly under FDA-approved standards
- Same packaging, same expiration dating, same chain-of-custody as pharmacy-distributed Zepbound
- Subject to FDA recall authority and post-marketing surveillance
Lilly Direct does not currently sell 12.5 mg or 15 mg vials. Patients on those doses must use the prefilled pen (which is not part of the cash program) or compounded tirzepatide.
How compounded tirzepatide differs in source and format
Compounded tirzepatide is prepared by 503A pharmacies using:
- Active pharmaceutical ingredient (API) sourced from FDA-registered API suppliers (typically in U.S., Europe, India, China)
- Excipients (preservatives, buffers, diluents) from pharmaceutical-grade suppliers
- Multi-dose vials, stoppers, and crimps
- Sterile compounding under USP <797> standards
- Pharmacy-specific quality control protocols
Format is similar to Lilly Direct vials: multi-dose vials drawn into separate syringes. The differences are at the source level:
| Attribute | Lilly Direct vials | Compounded tirzepatide |
|---|---|---|
| FDA approval | Yes | No |
| Manufacturing standard | FDA GMP | USP <797> (sterile compounding) |
| Oversight | FDA | State board of pharmacy |
| Source of active ingredient | Lilly's manufacturing supply chain | FDA-registered API supplier (varies by pharmacy) |
| Available doses | 2.5, 5, 7.5, 10 mg only | Any clinically appropriate dose |
| Combinations | Tirzepatide only | Optional combinations (B12, etc.) per pharmacy |
| Post-marketing surveillance | FDA MedWatch | Pharmacy-level adverse event reporting |
| Recall mechanism | FDA-mandated | Pharmacy-level recall, state board oversight |
The dose-by-dose cost comparison
| Dose | Lilly Direct vials | Brand Zepbound pen (retail) | Brand Zepbound pen (with insurance) | Compounded tirzepatide (typical) |
|---|---|---|---|---|
| 2.5 mg/week | $349/month | ~$1,059/month | $0-$25 with savings card + obesity coverage | $250-$300/month |
| 5 mg/week | $499/month | ~$1,059/month | $0-$25 | $300-$400/month |
| 7.5 mg/week | $499/month | ~$1,059/month | $0-$25 | $300-$400/month |
| 10 mg/week | $499/month | ~$1,059/month | $0-$25 | $350-$450/month |
| 12.5 mg/week | Not available | ~$1,059/month | $0-$25 | $400-$500/month |
| 15 mg/week | Not available | ~$1,059/month | $0-$25 | $400-$500/month |
Patterns:
- For patients with insurance coverage for Zepbound: brand with savings card ($0-$25) is the cheapest path regardless of dose
- For self-pay patients on doses 2.5-10 mg: Lilly Direct vials ($349-$499) typically beat or match compounded
- For self-pay patients on doses 12.5-15 mg: compounded tirzepatide is the lower-cost option since Lilly Direct does not offer those doses
- For patients who want non-standard doses (3.75 mg, 6.25 mg, etc.): compounded is the only path
Quality control: FDA approval vs 503A pharmacy practice
What FDA GMP standards ensure for Lilly Direct vials:
- Documented identity, potency, and purity of every batch
- Sterility validation
- Stability data supporting shelf life
- Traceability from raw material to dispensed product
- FDA inspection authority
- Post-marketing safety surveillance through MedWatch
- Manufacturer accountability for adverse events
What 503A compounding pharmacy oversight ensures (variably):
- State pharmacy board licensure
- USP <797> sterile compounding compliance (when adopted by state)
- Pharmacist licensure and continuing education
- Variable independent third-party testing (depends on pharmacy)
- State board inspection authority
- Variable adverse event reporting (depends on pharmacy practice)
The difference is not that compounded products are unsafe; it is that the safety net is thinner and more variable. Patients choosing compounded should evaluate the specific pharmacy's quality systems: ask about API sourcing, third-party testing, USP <797> compliance, and PCAB accreditation.
Dose flexibility: where compounding still has an edge
Brand Zepbound (pen or vial) is only available at the six FDA-approved strengths: 2.5, 5, 7.5, 10, 12.5, 15 mg.
Compounded tirzepatide can be prepared at intermediate strengths:
- 3.75 mg (between 2.5 and 5 mg starter levels)
- 6.25 mg (between 5 and 7.5 mg)
- 8.75 mg (between 7.5 and 10 mg)
- 11.25 mg (between 10 and 12.5 mg)
- Maintenance doses below 2.5 mg for taper scenarios
Clinical scenarios where intermediate doses matter:
- Patient cannot tolerate the next titration step but plateaued on the current dose
- Patient developing intolerance at top dose and needs gradual taper
- Patient at goal weight wants minimum effective maintenance dose
- Patient with renal impairment needing careful dose titration
This dose flexibility is one of the legally defensible reasons to compound tirzepatide in the post-shortage regulatory environment.
Custom formulations and combination products
503A pharmacies can formulate tirzepatide with additional ingredients. The most common combinations:
- Tirzepatide + vitamin B12 (cyanocobalamin)
- Tirzepatide + glycine (some platforms market this combination)
- Tirzepatide + L-carnitine
- Tirzepatide + NAD precursors
The clinical evidence for these specific combinations is limited. Vitamin B12 combinations have the strongest theoretical rationale (GLP-1 agonists may slow B12 absorption over time; B12 plays a role in energy metabolism), but trial-level evidence is sparse. Other combinations have even less supporting data.
Patients considering combination compounded products should ask their clinician what specific clinical rationale supports the combination for their situation. "The pharmacy offers it" is not a sufficient rationale.
Efficacy comparison: brand trial data and real-world expectations
Brand Zepbound benchmark data:
- SURMOUNT-1 (Jastreboff 2022): 22.5% mean weight loss at 72 weeks with 15 mg max dose
- SURMOUNT-5 (Aronne 2025): 20.2% mean weight loss at 72 weeks with 15 mg max dose, head-to-head vs Wegovy
- Real-world studies in 2025: typically 14-18% at 12 months
Compounded tirzepatide outcomes (when properly dosed):
- Should approximately match brand data because the molecule is identical
- Real-world adherence may differ from brand pen users (vials can be harder for needle-averse patients)
- Dose accuracy depends on syringe technique
- Quality of API and finished product depends on the pharmacy
No published trial has directly compared compounded tirzepatide to brand Zepbound. The mechanistic identity of the molecule provides the strongest argument for equivalent outcomes, but observational data is the only evidence base for compounded preparations specifically.
The contrary view: when brand Zepbound is the clear answer
Compounded tirzepatide has real cost and dose-flexibility advantages. Several scenarios make brand Zepbound clearly preferable:
Argument 1: Insurance coverage for Zepbound.
If insurance covers Zepbound with $0-$25 savings card, brand is cheaper than compounded. No reason to pay cash when insurance is paying.
Argument 2: Standard doses 2.5-10 mg with cost as the constraint.
Lilly Direct vials at $349-$499 are competitive with compounded prices. The brand option has FDA approval, GMP manufacturing, and post-marketing oversight that compounded does not. Same molecule, same vial format, more regulatory backing.
Argument 3: Patients who want regulatory and safety assurance.
FDA approval and ongoing oversight provide safety infrastructure that compounded medications lack. For risk-averse patients, brand is the conservative choice.
Argument 4: Patients in states with weak pharmacy oversight.
503A oversight quality varies by state. Patients in states with less rigorous state boards face higher variability in compounded product quality. Brand is uniform nationally.
Argument 5: Patients with the OSA indication.
Zepbound has an FDA-approved indication for obstructive sleep apnea in adults with obesity (December 2024). Compounded tirzepatide does not have any FDA-approved indication. For OSA patients, brand provides the regulatory pathway for coverage.
The counter: for patients on 12.5 or 15 mg doses without coverage, compounded tirzepatide remains meaningfully cheaper than brand pen pricing ($400-$500 vs ~$1,059/month). For patients needing custom doses, compounded is the only option. The decision is situation-specific.
Decision framework
Insurance covers Zepbound for obesity: brand Zepbound pen with savings card. $0-$25/month typical.
Self-pay, dose 2.5-10 mg: Lilly Direct vials ($349-$499/month). FDA-approved, vial format, competitive pricing.
Self-pay, dose 12.5-15 mg: compounded tirzepatide is typically the lower-cost path; brand pen is the more expensive but regulatorily clean alternative.
Need custom dose strength (3.75 mg, 6.25 mg, etc.): compounded is the only path.
Need a combination formulation (e.g., tirzepatide + B12): compounded only.
OSA indication and want insurance coverage: brand Zepbound; the OSA label is on Zepbound only.
Travel-heavy lifestyle: brand Zepbound (broader pharmacy network); compounded requires a specific 503A pharmacy relationship.
Maximum regulatory and safety assurance: brand Zepbound.
FAQ
Is compounded tirzepatide the same as brand Zepbound?
Same active molecule. Different FDA status, manufacturing, and oversight.
Why is the cost gap smaller than for semaglutide?
Lilly Direct's vial program at $349-$499/month for doses 2.5-10 mg narrowed it dramatically.
Is compounded tirzepatide legal?
Yes, under narrower 503A circumstances. Broad shortage-rule compounding ended October 2024.
Is compounded as effective as brand?
Should match at equivalent doses with proper compounding quality. No direct trial data.
How does the vial format compare?
Both are multi-dose vials with separate syringes; only the source differs.
Can I get high-dose tirzepatide through Lilly Direct?
Not currently. Vial program covers 2.5-10 mg only.
Quality control difference?
Brand under FDA GMP; compounded under state pharmacy board oversight. Compounded quality varies by pharmacy.
Can I switch?
Yes, clinically straightforward. New prescription required.
Does Lilly Direct work with insurance?
No. Cash-only. Not stackable with copay savings cards.
What does compounded cost?
$250-$450/month typical, varying by dose and pharmacy.
How do I evaluate a compounding pharmacy?
State board licensure, USP <797> sterile compounding, third-party testing of API and finished product, PCAB accreditation when available.
Can I use FSA/HSA for compounded tirzepatide?
Possibly, with proper documentation. Check with your plan administrator.
Related guides
- Semaglutide vs Tirzepatide Price: What You'll Actually Pay in 2026 for Brand and Compounded Versions
- Brand Mounjaro vs Compounded Tirzepatide Cost
- Brand Mounjaro vs Compounded Tirzepatide: Quality & Cost
- Compounded vs Brand Tirzepatide: What You Need to Know
- Compounded Tirzepatide Vs Zepbound: Complete Comparison
- What's the Difference Between Ozempic and Semaglutide? The Complete Brand vs Generic vs Compounded Breakdown
Sources
- FDA. Zepbound (tirzepatide) prescribing information. Initial approval November 2023; OSA indication December 2024.
- FDA. Mounjaro (tirzepatide) prescribing information. Most recent revision 2025.
- Eli Lilly. Lilly Direct vial program for Zepbound. Launched August 2024, expanded 2025.
- FDA. Drug Shortage List, tirzepatide injection. Resolved October 2024.
- FDA. Drug Quality and Security Act Section 503A and 503B compounding regulations.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity: SURMOUNT-1. New England Journal of Medicine. 2022.
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: SURMOUNT-5. New England Journal of Medicine. 2025.
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity: SURMOUNT-OSA. New England Journal of Medicine. 2024.
- United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding: Sterile Preparations.
- Pharmacy Compounding Accreditation Board (PCAB). Accreditation standards. 2024-2025.
- FDA. Warning letters to compounding pharmacies regarding tirzepatide products. 2024-2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that pairs patients with independent licensed prescribers and U.S. state-licensed compounding pharmacies. We do not manufacture, prescribe, or dispense medication ourselves. All treatment recommendations are made by independent licensed clinicians.
Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is not legally interchangeable with brand-name Zepbound or Mounjaro. It is prepared by state-licensed 503A pharmacies in response to individual patient prescriptions and has not undergone FDA review for safety, efficacy, or manufacturing consistency. Quality varies by pharmacy.
Results Disclaimer. Clinical outcomes referenced reflect brand tirzepatide trial data (SURMOUNT-1, SURMOUNT-5, SURMOUNT-OSA) and may not directly translate to compounded preparations. Real-world outcomes vary based on dose, adherence, lifestyle, baseline health, and the specific compounding pharmacy's product quality.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Lilly Direct is a direct-to-patient pharmacy program operated by Eli Lilly. SURMOUNT is a clinical trial program of Eli Lilly. FormBlends is not affiliated with, sponsored by, or endorsed by Eli Lilly or its programs.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →